An Orphan Reinsurer Benefit Manager (ORBM) could address the financial challenges (payment timing, therapeutic performance risk, actuarial risk), created by durable/potentially curable gene and cell therapies especially for smaller insurers … Read More
PPD, Evidera join NEWDIGS Initiative at MIT as a Strategic Partner
Collaboration to drive innovation across health care ecosystem WILMINGTON, N.C., May 22, 2018– Pharmaceutical Product Development, LLC (PPD), and its real-world research and market access business unit, Evidera, have joined the Massachusetts Institute … Read More
NEWDIGS in the world, May 2018
NEWDIGS leadership and thinking at recent international gatherings Gigi Hirsch and R. John Glasspool at LIGHT 2018 The second annual LIGHT Forum (Leaders in Global Healthcare and Technology) took place … Read More
NEWDIGS leaders speak at second LIGHT Forum on technology innovation in healthcare
Gigi Hirsch and R. John Glasspool join other innovation leaders to explore the challenges and potential of new technologies for patient care San Mateo, Calif., May 9, 2018 – The … Read More
Precision Financing strategies explored in FoCUS Design Lab
Healthcare innovation stakeholders co-develop solutions to make curative therapies accessible to patients, propose new pilot project CAMBRIDGE, MASSACHUSETTS—The NEWDrug Development ParadIGmS (NEWDIGS) initiative at the MIT Center for Biomedical Innovation (CBI) hosted … Read More
Impact of Actuarial Risk on Health Plans
The uncertain number of patients likely to be treated with an expensive novel therapy (actuarial risk) could represent a major financial issue for some payers. In this brief, we will … Read More
FoCUS Project: Recent International Event Highlights (April 2018)
NEWDIGS FoCUS project leaders have appeared in three recent meetings to share emerging perspectives on financing potentially durable but expensive new therapies. Casey Quinn and R. John Glasspool speak at … Read More
Designing Precision Financing for Cures
Designing Precision Financing for cures can be informed by a framework that tailors solutions to the three financing challenges of actuarial risk, performance risk and payment timing based on the … Read More
The heterogeneity of health care payers suggests that durable therapies need precision financing targeted to each payer segment
FoCUS participants have identified four payer segments for precision financing: self-insured employers and related organizations; health insurance plans and managed care organizations; Medicare; and Medicaid. Download FoCUS Research Brief_2018F202-014Share the … Read More
Interview with Mark Trusheim for ADAPT SMART
Road MAPPs to therapeutic innovation One of the original thought leaders of the concept of Adaptive Pathways was the NEWDIGS initiative of MIT’s Center for Biomedical Innovation. ADAPT SMART has … Read More